Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells

Stroncek, David F.; Clay, Mary; Petzoldt, Martin; Smith, Julius; Jaszcz, W; Oldham, Fred B.; McCullough, Jeffrey

doi:10.1046/j.1537-2995.1996.36796323059.x

Cited by 231 publications

(226 citation statements)

References 24 publications

(1 reference statement)

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…[32][33][34] However, our institution had adopted the Food and Drug Administration-approved dose schedule for 'PBPC collection and therapy for cancer patients,' which, by label, is 10 mg/kg/day by s.c or continuous infusion. 35 Using this strategy, there certainly is a possible risk of under-dosing, therefore, based on a desire to limit drug wastage.…”

Section: Discussionmentioning

confidence: 99%

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Fowler

Dunn

Hayes-Lattin

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Fowler

Dunn

Hayes-Lattin

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Most common or "expected" side effects are mild to moderate, with bone pain, myalgia, malaise and nausea being the most frequently occurring (Figure 1) [17]. Many donors describe their symptoms collectively as "flu-like symptoms".…”

Section: Allogeneic Peripheral Blood Stem Cell Collectionmentioning

confidence: 99%

“…This should ideally be established through the peripheral antecubital veins if they are large enough to accommodate a [16][17][18] [32]. Middle-age women seem to be at particular risk for this [11].…”

Section: Vascular Accessmentioning

confidence: 99%

Allogeneic peripheral blood stem cell collection as of 2008

Rhodes

Anderlini

2008

Transfusion and Apheresis Science

View full text Add to dashboard Cite

The rapid growth of the use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to mobilize and collect allogeneic peripheral blood stem cells (PBSCs) for transplantation has made it a new international standard. While the procedure remains safe, older donors, donors with significant comorbidities and pediatric donors are now often employed. This brings a new set of challenges in the donor evaluation, medical clearance, informed consent and collection process. Rare and unexpected severe adverse events related to rhG-CSF administration and PBSC apheresis have been described. Proper PBSC donor counseling, evaluation and care have become even more important.

show abstract

“…11 Thrombocytopenia was observed in our study, because the platelets were lost along with PBSC components and the platelet production was suppressed by G-CSF. 12 After a collection of G-CSF-mobilized PBSC from healthy donors, the platelet count fell and remained lower for seven to 10 days. 13 The careful monitoring of platelet counts is indispensable.…”

Section: Discussionmentioning

confidence: 99%

Collection of peripheral blood stem cells with granulocyte‐colony‐stimulating factor alone in testicular cancer patients

et al. 2000

View full text Add to dashboard Cite

Background: High-dose chemotherapy with the transplantation of peripheral blood stem cells (PBSC) has been performed for the treatment of advanced testicular cancer patients. Recently, it has been reported that, in healthy donors, a large quantity of stem cells can be transferred to peripheral blood using granulocyte-colony-stimulating factor (G-CSF) alone. Therefore, it was decided to try to harvest PBSC from three patients having testicular cancers with G-CSF alone. Methods:The three patients with testicular cancer were 26, 56 and 62-years-old. They had undergone five, two and three cycles of chemotherapy, respectively, but no radiation therapy. Granulocyte colony-stimulating factor was subcutaneously injected (250 mg) into each patient twice per day for 6 days. Peripheral blood stem cells were harvested for 3 days (days 4-6) and mononuclear cells (MNC), CD34-positive cells and colony-forming units of granulocyte-macrophage (CFU-GM) in PBSC collected by apheresis were measured. Results: Apheresis showed that the total MNC count was 20.2 ¥ 10 8 /kg (range, 10.6-25.9 ¥ 10 8 /kg), the CD34-positive cell count was 0.98 ¥ 10 6 /kg (range, 0.75-1.4 ¥ 10 6 /kg) and the total CFU-GM count was 1.36 ¥ 10 5 /kg (range, 0.25-3.0 ¥ 10 5 /kg). Conclusion: After mobilization of peripheral blood stem cells with G-CSF alone, sufficient amounts of MNC were obtained from testicular cancer patients who had undergone chemotherapy several times. However, sufficient amounts of CD34-positive cells and CFU-GM could not be obtained. These results suggested that the G-CSF dose was not adequate for harvesting sufficient amounts of CD34-positive cells and CFU-GM.

show abstract

Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells

Cited by 231 publications

References 24 publications

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Allogeneic peripheral blood stem cell collection as of 2008

Collection of peripheral blood stem cells with granulocyte‐colony‐stimulating factor alone in testicular cancer patients

Contact Info

Product

Resources

About